Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches

Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.

(2019) Teresa Troiani et al.   JOURNAL OF CLINICAL ONCOLOGY

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

(2019) Eric Xueyu Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.

(2019) Maria Pia Morelli et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA-004Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

(2018) J Bendell et al.   ANNALS OF ONCOLOGY

Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer

(2018) Takeshi Ishikawa et al.   INTERNATIONAL JOURNAL OF CANCER

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

(2018) Felix S. Lichtenegger et al.   Frontiers in Immunology

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer

(2018) Magalie Dosset et al.   OncoImmunology

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

(2018) Alexander Stein et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA37_PRNeoadjuvant ipilimumab plus nivolumab in early stage colon cancer

(2018) M Chalabi et al.   ANNALS OF ONCOLOGY

LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

(2018) A Grothey et al.   ANNALS OF ONCOLOGY

LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

(2018) H-J J Lenz et al.   ANNALS OF ONCOLOGY

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).

(2017) Howard S. Hochster et al.   JOURNAL OF CLINICAL ONCOLOGY

Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation

(2017) Jun Gong et al.   Journal of the National Comprehensive Cancer Network

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

(2017) Samra Turajlic et al.   LANCET ONCOLOGY

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Oncolytic Viruses in Cancer Treatment

(2017) Sean E. Lawler et al.   JAMA Oncology

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

(2016) J. Chesney et al.   ANNALS OF ONCOLOGY

The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment

(2016) LUBOS HOLUBEC et al.   ANTICANCER RESEARCH

Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy

(2016) Etienne Becht et al.   CLINICAL CANCER RESEARCH

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer.

(2016) Austin G. Duffy et al.   JOURNAL OF CLINICAL ONCOLOGY

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

(2016) Marios Giannakis et al.   Cell Reports

Chimeric antigen receptor T-cell therapy for solid tumors

(2016) Kheng Newick et al.   Molecular Therapy-Oncolytics

Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer

(2015) Yun-Huan Zhen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

(2015) Kobe Reynders et al.   CANCER TREATMENT REVIEWS

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors

(2015) Hinrich Abken   Immunotherapy

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

(2015) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

(2015) Se Hoon Park et al.   MOLECULAR THERAPY

The consensus molecular subtypes of colorectal cancer

(2015) Justin Guinney et al.   NATURE MEDICINE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

(2015) Patrick A. Ott et al.   Frontiers in Oncology

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

(2014) Hans-Joachim Schmoll et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

(2014) Nicolas J. Llosa et al.   Cancer Discovery

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

(2013) Paul F Robbins et al.   NATURE MEDICINE

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regulation of Adaptive Immunity by the Innate Immune System

(2010) A. Iwasaki et al.   SCIENCE